October 2011

Agile Sciences receives NIH STTR grant to evaluate anti-biofilm compounds for treating cystic fibrosis in collaboration with Dr. Richard Boucher at UNC Chapel Hill. News release.

October 2011

Agile Sciences and Calvert Research announce strategic collaboration. News release.

September 2011

A $545,000 NIH Phase I SBIR SHIFT Grant is awarded to Agile Sciences to support human therapeutic development. News release.

July 2011

Agile Sciences is awarded a NIH Phase I STTR Grant to evaluate technology in chronic wound models at the Center for Biofilm Engineering at Montana State Universtiy. News release.

More News...

Agile Sciences founders John Cavanagh and Christian Melander analyze the results of anti-biofilm screening tests.

The co-founders of Agile Sciences have developed compounds that can disperse colonies of bacteria called biofilms. These compounds have applications in the areas of medicine, agriculture, and industry.

Biofilms that form in the human body are up to ten thousand times more resistant to antibiotics and immune systems than free-floating bacteria, making them very difficult to treat medically. In agriculture, every year billions of dollars of crops are lost due to the formation of biofilms. Industrial needs for effective biofilm dispersion include surface coatings and cleansing products.

Agile Sciences' technology addresses problems associated with biofilm formation through the use of proprietary non-toxic organic compounds.